Your browser is no longer supported. Please, upgrade your browser.
Settings
INO Inovio Pharmaceuticals, Inc. daily Stock Chart
INO [NASD]
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own2.60% Shs Outstand96.79M Perf Week-19.74%
Market Cap358.12M Forward P/E- EPS next Y-0.98 Insider Trans-2.29% Shs Float89.55M Perf Month-24.64%
Income-85.50M PEG- EPS next Q-0.28 Inst Own35.20% Short Float7.19% Perf Quarter-23.55%
Sales36.80M P/S9.73 EPS this Y-7.10% Inst Trans0.41% Short Ratio6.75 Perf Half Y-16.48%
Book/sh1.12 P/B3.30 EPS next Y1.00% ROA-52.60% Target Price10.67 Perf Year-11.48%
Cash/sh0.88 P/C4.19 EPS next 5Y0.00% ROE-72.70% 52W Range3.64 - 6.30 Perf YTD-7.50%
Dividend- P/FCF- EPS past 5Y-13.40% ROI-58.70% 52W High-41.27% Beta1.84
Dividend %- Quick Ratio3.30 Sales past 5Y59.30% Gross Margin- 52W Low1.65% ATR0.26
Employees278 Current Ratio3.30 Sales Q/Q-23.10% Oper. Margin- RSI (14)27.31 Volatility3.94% 4.27%
OptionableYes Debt/Eq0.00 EPS Q/Q31.10% Profit Margin- Rel Volume4.28 Prev Close3.69
ShortableYes LT Debt/Eq0.00 EarningsMar 13 AMC Payout- Avg Volume953.74K Price3.70
Recom- SMA20-22.75% SMA50-21.46% SMA200-22.40% Volume4,084,890 Change0.27%
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Sep-06-17Initiated Citigroup Buy $10
Jun-08-17Upgrade Piper Jaffray Neutral → Overweight
May-24-17Reiterated Maxim Group Buy $10 → $12
Mar-16-17Upgrade Maxim Group Hold → Buy $10
Mar-16-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-16Initiated Aegis Capital Buy
Aug-09-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Stifel Buy $19 → $13
Jan-05-16Reiterated Maxim Group Buy $23 → $14
Sep-09-15Reiterated Maxim Group Buy $20 → $23
Mar-12-15Initiated H.C. Wainwright Buy $17
Jul-24-14Upgrade Aegis Capital Hold → Buy $10 → $19
May-07-14Initiated Stifel Buy $4
Mar-18-14Reiterated Maxim Group Buy $3 → $6
Jan-24-14Reiterated Brean Capital Buy $3 → $4
Aug-16-13Downgrade Aegis Capital Buy → Hold
Jul-09-13Reiterated Maxim Group Buy $1 → $2
Mar-11-13Initiated Aegis Capital Buy $1.50
Feb-15-19 09:47AM  Montco biopharm firm plans $65M note sale; stock drops by 22 percent American City Business Journals
Feb-14-19 12:00PM  Here's Why Inovio Pharmaceuticals Is Getting Beaten Down Today Motley Fool -21.15%
07:50AM  The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial Benzinga
07:00AM  Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering PR Newswire
Feb-13-19 04:01PM  Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering PR Newswire
Jan-28-19 05:26PM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks -5.69%
Jan-24-19 01:30PM  4 Pharma Stocks Leading Thursday's Bull Charge ACCESSWIRE
08:47AM  Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor PR Newswire
08:32AM  Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor PR Newswire
Jan-23-19 12:19PM  Have Insiders Been Selling Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares? Simply Wall St.
Jan-15-19 08:00AM  Inovio's dMAb PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies PR Newswire
Jan-14-19 10:22AM  Can Inovio Pharmaceuticals Stock Keep Bounding Higher? Motley Fool -6.82%
Jan-10-19 10:00AM  Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect Zacks
Jan-09-19 09:50AM  Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan Zacks
Jan-07-19 10:09AM  Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed Zacks +7.17%
08:00AM  Inovio's DNA-Encoded Monoclonal Antibody (dMAb) Platform Leaps Forward with First-in-Human Trial PR Newswire
08:00AM  Inovio's DNA-Encoded Monoclonal Antibody (dMAb(TM)) Platform Leaps Forward with First-in-Human Trial PR Newswire
Jan-04-19 06:29PM  Jazz Inks Deal with Codiak to Develop Exosome Therapeutics Zacks +7.48%
10:01AM  Vertex Joins Forces With Arbor to Build Gene-Editing Therapies Zacks
Jan-03-19 09:30AM  Novo Nordisk Boasts Strong Diabetes Presence and Pipeline Zacks
08:00AM  Inovio Announces Appointments to its Board of Directors PR Newswire
Dec-28-18 08:29AM  Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group Zacks
Dec-27-18 08:25AM  AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions Zacks
Dec-17-18 12:59PM  Do Insiders Own Lots Of Shares In Inovio Pharmaceuticals, Inc. (NASDAQ:INO)? Simply Wall St.
Dec-08-18 06:19PM  RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
09:30AM  Why Is Inovio (INO) Down 0.6% Since Last Earnings Report? Zacks
Dec-05-18 09:49AM  Inovio (INO) to Receive Milestone Payment From AstraZeneca Zacks
Dec-04-18 08:00AM  Inovio Announces Initiation of MD Andersons HPV-Related Cancers Moon Shot Phase 2 Trial in New HPV Indications GlobeNewswire
Nov-26-18 08:50AM  Consolidated Research: 2018 Summary Expectations for Ur Energy, SilverCrest Metals, Norwegian Cruise Line, Inovio Pharmaceuticals, Spok, and SunLink Health Fundamental Analysis, Key Performance Indications GlobeNewswire
08:00AM  Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019 GlobeNewswire
Nov-20-18 09:10AM  Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint Zacks
Nov-15-18 08:00AM  Inovio Prepares for Growth & Commercialization With Leadership Appointments GlobeNewswire
Nov-14-18 10:15AM  Merck Starts Rolling BLA Submission for Ebola Vaccine V920 Zacks
Nov-09-18 10:34AM  Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet Zacks
Nov-08-18 11:36PM  Edited Transcript of INO earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
07:35PM  Inovio Pharmaceuticals (INO) Reports Q3 Loss, Lags Revenue Estimates Zacks
06:30PM  Inovio: 3Q Earnings Snapshot Associated Press
04:05PM  Inovio Pharmaceuticals Reports 2018 Third Quarter Financial Results GlobeNewswire
Nov-07-18 02:56PM  What does Inovio Pharmaceuticals Incs (NASDAQ:INO) Balance Sheet Tell Us About Its Future? Simply Wall St.
Nov-05-18 08:00AM  Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences GlobeNewswire
Oct-25-18 08:00AM  Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses GlobeNewswire
Oct-24-18 08:00AM  Inovio Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 8, 2018 GlobeNewswire -8.24%
Oct-22-18 08:00AM  Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150 GlobeNewswire
Oct-17-18 08:00AM  Inovios DNA-Encoded Monoclonal Antibody (dMAb) Platform Moves Ahead with Positive Data, Patents and Grants GlobeNewswire
Oct-15-18 08:00AM  Inovios Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies GlobeNewswire
Oct-09-18 07:50AM  Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-08-18 08:00AM  Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies GlobeNewswire
Oct-05-18 10:30AM  Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up Zacks
Oct-03-18 08:00AM  Todays Research Reports on Stocks to Watch: Inovio Pharmaceuticals and vTV Therapeutics ACCESSWIRE
Oct-02-18 12:18PM  Why Inovio Pharmaceuticals, Inc. Stock Is Soaring Today Motley Fool +14.21%
08:00AM  Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor GlobeNewswire
Sep-23-18 04:10PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-18-18 10:30AM  Undervalued Cannabis and Biotech Stocks ACCESSWIRE
07:31AM  Inovio Pharmaceuticals (INO): Moving Average Crossover Alert Zacks
Sep-17-18 08:00AM  Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges GlobeNewswire
Sep-16-18 02:22PM  The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-11-18 06:26PM  Edited Transcript of INO earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-10-18 10:29AM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks
Sep-07-18 01:44PM  How Inovio Pharmaceuticals Inc (NASDAQ:INO) Can Impact Your Portfolio Volatility Simply Wall St.
11:03AM  Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine Zacks
Sep-06-18 06:00AM  Why Inovio Pharmaceuticals Inc. Stock Bolted Higher in August Motley Fool
Sep-05-18 08:00AM  Inovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection GlobeNewswire
Sep-04-18 11:30AM  Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine Zacks
01:00AM  Inovio and Korean Partner Dose 1st Subject In Trial to Develop Worlds First Vaccine to Prevent Hepatitis C Infection GlobeNewswire
Aug-23-18 08:00AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Inovio Pharmaceuticals ACCESSWIRE
Aug-21-18 08:00AM  Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences GlobeNewswire
Aug-16-18 12:09PM  Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study Zacks
08:00AM  Inovio Treats First Patient in Immuno-Oncology Study for Advanced or Metastatic Bladder Cancer in Combination with Roche/Genentechs Atezolizumab GlobeNewswire
Aug-15-18 06:02AM  5 Promising Vaccines in Development -- and the Stocks Poised to Profit From Them Motley Fool
Aug-14-18 08:00AM  Inovio Announces First Patient Dosed in Trial to Determine PENNVAX®-GPs Ability to Induce Remission of HIV Infection GlobeNewswire
Aug-09-18 08:00AM  Todays Research Reports on Stocks to Watch: Inovio Pharmaceuticals and Ampio Pharmaceuticals ACCESSWIRE
Aug-08-18 12:41PM  Why Inovio Pharmaceuticals, Inc. Stock Is Jumping 12.4% Today Motley Fool +11.44%
10:30AM  Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates Zacks
06:02AM  These 3 Things Are All That Matter in Inovio Pharmaceuticals' Q2 Results Motley Fool
Aug-07-18 08:15PM  Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:08PM  Inovio: 2Q Earnings Snapshot Associated Press
04:05PM  Inovio Pharmaceuticals Reports 2018 Second Quarter Financial Results GlobeNewswire
Aug-06-18 12:28PM  Plymouth Meeting-based Inovio teams up with AIDS Malignancy Consortium for immunotherapy study American City Business Journals
11:35AM  What's in the Cards for Inovio (INO) This Earnings Season? Zacks
08:00AM  Inovio Partners with AIDS Malignancy Consortium to Advance Inovios HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients GlobeNewswire
Aug-01-18 07:50AM  Recent Analysis Shows Getty Realty, Keysight Technologies, Inovio Pharmaceuticals, Air Transport Services Group, Asure Software, and J.Jill Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-26-18 06:32AM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation Motley Fool
Jul-24-18 08:00AM  Inovio Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-13-18 07:30AM  Free Technical Research on Insmed and Three More Biotech Equities ACCESSWIRE
Jul-08-18 11:42AM  Is Inovio Pharmaceuticals, Inc. a Buy? Motley Fool
Jun-27-18 08:00AM  Inovios MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study GlobeNewswire
Jun-22-18 08:18AM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc. Motley Fool
Jun-21-18 08:00AM  Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regenerons PD-1 Inhibitor GlobeNewswire
Jun-16-18 07:33AM  Are These 2 Dark Horse Vaccine Makers Worth the Risk? Motley Fool
Jun-08-18 08:45AM  Inovio (INO) Down 5.8% Since Earnings Report: Can It Rebound? Zacks
May-31-18 08:00AM  Inovio CEO to Speak on Viral Epidemic Preparedness Panel at BIO International Convention GlobeNewswire
May-24-18 08:00AM  Inovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D GlobeNewswire
May-22-18 12:01PM  Inovio Initiates Phase II Study on Pipeline Drug VGX-3100 Zacks
May-21-18 08:00AM  Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV The No. 1 Sexually Transmitted Disease GlobeNewswire
May-18-18 04:03AM  Edited Transcript of INO earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-17-18 08:00AM  Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer GlobeNewswire
May-16-18 08:45AM  Inovio Pharmaceuticals (INO) in Focus: Stock Moves 5.7% Higher Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics, Inc. and Inovio Pharmaceuticals ACCESSWIRE
May-15-18 08:00AM  Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial GlobeNewswire +5.71%
May-10-18 12:51PM  Inovio's (INO) Q1 Loss Wider than Expected, Shares Down Zacks -9.11%
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DHILLON AVTAR SDirectorDec 06Option Exercise2.0025,00050,000106,002Dec 06 05:17 PM
KIES PETERCFONov 29Option Exercise2.0010,00120,00272,089Nov 30 05:27 PM
KIES PETERCFONov 29Sale5.2810,00152,80562,088Nov 30 05:27 PM
Kim Jong JosephChief Executive OfficerSep 12Option Exercise5.0849,060249,2252,357,554Sep 14 05:12 PM
Kim Jong JosephChief Executive OfficerSep 12Sale5.3749,060263,4522,308,494Sep 14 05:12 PM
KIES PETERCFOJul 10Sale4.4510,00044,50062,088Jul 11 05:05 PM
KIES PETERCFOJul 09Option Exercise4.2415,00063,60097,088Jul 11 05:05 PM
KIES PETERCFOJul 09Sale4.4325,000110,75072,088Jul 11 05:05 PM
Weiner David B.DirectorApr 16Sale4.919,00044,203758,956Apr 19 04:35 PM
Kim Jong JosephChief Executive OfficerApr 13Option Exercise2.16107,500232,2002,399,307Apr 13 06:35 PM
Kim Jong JosephChief Executive OfficerApr 13Sale5.06107,500543,4132,291,807Apr 13 06:35 PM
BENITO SIMON XDirectorApr 12Option Exercise3.563,75013,35031,548Apr 13 06:20 PM
Kim Jong JosephChief Executive OfficerApr 12Option Exercise2.40103,750249,0002,395,557Apr 13 06:35 PM
Kim Jong JosephChief Executive OfficerApr 12Sale5.14103,750533,1402,291,807Apr 13 06:35 PM
BENITO SIMON XDirectorApr 12Sale5.233,75019,61927,798Apr 13 06:20 PM